China’s BlissBio Is Said to Be Considering Hong Kong IPO

BlissBio, a Chinese company that develops treatments for cancer, is considering an initial public offering in Hong Kong, according to people familiar with the matter.

The clinical stage biotech firm is working with advisers to help arrange the potential share sale, which could raise at least $150 million, the people said, asking not to be identified because the information is private.

Talks are ongoing and details such as the size of the IPO could change, the people said. BlissBio may also decide not to go ahead with a listing, they said.

A representative for BlissBio declined to comment.

Hong ...